Open AccessGonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
Author(s) -
Juan Carlos Castillo,
Thor Haahr,
María Martínez-Moya,
Peter Humaıdan
Publication year - 2020
Publication title -
upsala journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.808
H-Index - 41
eISSN - 2000-1967
pISSN - 0300-9734
DOI - 10.1080/03009734.2020.1737599
Subject(s) - ovarian hyperstimulation syndrome , medicine , gonadotropin releasing hormone agonist , oocyte , ovulation , in vitro fertilisation , agonist , ovulation induction , assisted reproductive technology , gonadotropin , hormone , gonadotropin releasing hormone , andrology , gynecology , endocrinology , infertility , pregnancy , embryo , receptor , biology , luteinizing hormone , genetics , microbiology and biotechnology
In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention. The GnRHa trigger concept has sparked the development of novel protocols, enriching the assisted reproductive technology (ART) armamentarium for the benefit of present and future patients. Thus, GnRHa trigger already has a pivotal role, not only for the standard in vitro fertilisation (IVF) patient, but also for patient groups like oocyte donors, cancer patients, patients with poor ovarian reserve, and patients with immature oocyte syndrome and empty follicle syndrome. Herein, we discuss the importance of the GnRHa-elicited midcycle FSH surge and the potential improvement in oocyte yield and embryo competence.